Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination.
作者信息
Rosati Margherita, Terpos Evangelos, Agarwal Mahesh, Karalis Vangelis, Bear Jenifer, Burns Robert, Hu Xintao, Papademetriou Demetrios, Ntanasis-Stathopoulos Ioannis, Trougakos Ioannis P, Dimopoulos Meletios-Athanasios, Pavlakis George N, Felber Barbara K
机构信息
Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
出版信息
Am J Hematol. 2022 Jan 1;97(1):E3-E7. doi: 10.1002/ajh.26380. Epub 2021 Nov 5.
Abstract
摘要
相似文献
1
Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination.
Am J Hematol. 2022 Jan 1;97(1):E3-E7. doi: 10.1002/ajh.26380. Epub 2021 Nov 5.
2
Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.
Clin Transl Med. 2021 Dec;11(12):e644. doi: 10.1002/ctm2.644.
3
A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
Cell Rep Med. 2021 Dec 14;3(1):100486. doi: 10.1016/j.xcrm.2021.100486. eCollection 2022 Jan 18.
4
Establishment of human post-vaccination SARS-CoV-2 standard reference sera.
J Immunol Methods. 2024 Jul;530:113698. doi: 10.1016/j.jim.2024.113698. Epub 2024 May 31.
5
Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Front Immunol. 2021 Dec 17;12:793191. doi: 10.3389/fimmu.2021.793191. eCollection 2021.
6
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.
7
Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera.
J Mol Cell Biol. 2022 Jan 29;13(12):918-920. doi: 10.1093/jmcb/mjab050.
8
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
Nat Med. 2022 Mar;28(3):496-503. doi: 10.1038/s41591-022-01715-4. Epub 2022 Jan 28.
9
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
Cell. 2022 Feb 3;185(3):447-456.e11. doi: 10.1016/j.cell.2021.12.032. Epub 2021 Dec 24.
10
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
mBio. 2021 Jun 29;12(3):e0069621. doi: 10.1128/mBio.00696-21. Epub 2021 Jun 1.
引用本文的文献
1
Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study.
Viruses. 2023 Nov 13;15(11):2250. doi: 10.3390/v15112250.
2
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.
Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.
3
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
4
Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies.
Eur J Intern Med. 2023 Jan;107:7-16. doi: 10.1016/j.ejim.2022.11.009. Epub 2022 Nov 10.
5
Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV conserved elements in macaques.
Front Immunol. 2022 Jul 22;13:945706. doi: 10.3389/fimmu.2022.945706. eCollection 2022.
6
Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.
Front Immunol. 2022 May 25;13:899972. doi: 10.3389/fimmu.2022.899972. eCollection 2022.
7
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222.
Biomedicines. 2022 Feb 1;10(2):338. doi: 10.3390/biomedicines10020338.
8
Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis.
Biomedicines. 2022 Jan 18;10(2):204. doi: 10.3390/biomedicines10020204.
9
Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS-CoV-2: Results of a prospective study in 150 health professionals in Greece.
Am J Hematol. 2022 Apr;97(4):E147-E150. doi: 10.1002/ajh.26468. Epub 2022 Jan 25.
10
Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals.
Hemasphere. 2021 Dec 17;6(1):e677. doi: 10.1097/HS9.0000000000000677. eCollection 2022 Jan.
本文引用的文献
1
Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections.
BMC Med. 2021 Oct 1;19(1):255. doi: 10.1186/s12916-021-02103-4.
2
Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques.
PLoS Pathog. 2021 Sep 22;17(9):e1009701. doi: 10.1371/journal.ppat.1009701. eCollection 2021 Sep.
3
Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals.
Cell Rep. 2021 Aug 24;36(8):109570. doi: 10.1016/j.celrep.2021.109570. Epub 2021 Aug 4.
4
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.
Science. 2021 Sep 17;373(6561):1372-1377. doi: 10.1126/science.abj4176. Epub 2021 Aug 13.
5
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.
Wien Klin Wochenschr. 2021 Sep;133(17-18):931-941. doi: 10.1007/s00508-021-01922-y. Epub 2021 Aug 10.
6
Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection.
Sci Transl Med. 2021 Sep;13(609):eabj0847. doi: 10.1126/scitranslmed.abj0847. Epub 2021 Aug 5.
7
Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients.
Cell Rep. 2021 Aug 10;36(6):109504. doi: 10.1016/j.celrep.2021.109504. Epub 2021 Jul 23.
8
Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021.
MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1059-1062. doi: 10.15585/mmwr.mm7031e2.
9
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.
N Engl J Med. 2021 Oct 14;385(16):1474-1484. doi: 10.1056/NEJMoa2109072. Epub 2021 Jul 28.
10
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.
Zotero 插件